National Dementia Diagnostics Laboratory

The National Dementia Diagnostics Laboratory (NDDL)  is located at the Florey Institute of Neuroscience and Mental Health, in conjunction with the University of Melbourne.

The NDDL closes for Victorian and National Public Holidays. Please hold all diagnostic samples at -20 degrees celsius during affected periods. Contact us for further information about Specimen Reception at the NDDL. 

Cerebrospinal Fluid Alzheimer Disease Screen

Abeta1-42, Tau, Phospho-Tau

The Cerebrospinal Fluid (CSF) Alzheimer Disease Screen is an ante-mortem diagnostic test that detects alterations in the levels of biomarker proteins, specifically amyloid Abeta42, total-tau and phospho-tau, which are believed to be directly related to the pathophysiology of Alzheimer's disease (AD). Based on international experience, these CSF biomarkers offer approximately 80-90% sensitivity and specificity for clinically overt AD and valuable prognostic information in persons with amnestic mild cognitive impairment (1). The recommendations detailed for CSF handling align with the consensus statement issued by the Alzheimer's Biomarker Standardisation Initiative (2,3).

NDDL is the NATA/ILAC accredited diagnostic laboratory in Australia that provides CSF diagnostic screening for Alzheimer’s disease (Abeta 1-42/total-tau/phospho-tau proteins). 

The sample:

Diagnostic Testing Fees (non-rebatable)

AD screen (three proteins)  $250; any two proteins  $200; any single protein  $150

The test is run fortnightly, except insufficient samples.

References:

  1. Li et al. Alzheimer disease normative CSF biomarkers validated in PET Aβ characterized subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Alzheimer’s Dis. 2015; 48:175–187; Hulstaet et al. Neurology 1999; 52:1555; Hansson et al., Lancet Neurol, 2006;5(3):228-34; Buchhave et al. Arch Gen Psychiatry 2012; 69: 98-106; Li et al. J Clin Neurosci. 2018 Feb 5. doi: 10.1016/j.jocn.2018.01.064
  2. Vanderstichele et al. Alzheimer's and Dementia 2012; 8:65-73.
  3. This laboratory is a member of the Alzheimer's Association QC program.

NDDL management

Prof. Steven Collins

Prof. Colin Masters

Contact/Courier details

Email: enquiries-nddl@unimelb.edu.au
Phone: (03) 9035 7243
Facsimile: (03) 9035 8768

Dr Qiao-Xin Li
National Dementia Diagnostics Laboratory
Florey Institute of Neuroscience and Mental Health
Kenneth Myer Building / Melbourne Brain Centre
30 Royal Parade (corner of Genetics Lane)
Enter via Gate 11, rear loading dock
Parkville Victoria 3010

Cerebrospinal Fluid Creutzfeldt Jakob disease Screen

14-3-3 and Tau Protein Test

The 14-3-3 and tau proteins are non-specific, ante-mortem markers of central nervous system neuronal injury or death. Based on international experience in carefully selected patients, a positive result has approximately 80-90% sensitivity and specificity for sporadic Creutzfeldt-Jakob disease. While most often concordant, the two protein biomarkers should be viewed as complementary. False positives are recognized in various disease processes; for example encephalitis, encephalopathies and recent cerebral infarcts. Consequently, unselected sampling is less reliable as screening for a possible diagnosis of sporadic CJD. 

The NDDL/Australian National Creutzfeldt-Jakob disease Registry (ANCJDR) is the only NATA accredited diagnostic laboratory in Australia that provides 14-3-3 and Tau CSF protein testing.

For specific details regarding the specimen requirements and reception, please refer to the main ANCJDR website or contact the ANCJDR main office on Phone: 61 3 8344 1949 or Email:  ancjd-reg@unimelb.edu.au

Support us

Brain health affects all Australians.
You can support our research by making a donation or a bequest.

Newsletter

Latest breakthroughs, news, events & more.